ズーラ・バイオ
Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.21 | $0 | -$21M |
| 2026 Q1 | -0.22 | $0 | -$19M |
| 2025 Q4 | -0.49 | $0 | -$22M |
| 2025 Q3 | -0.21 | $0 | -$15M |
| 2025 Q2 | -0.17 | $0 | -$16M |
| 2025 Q1 | -0.19 | $0 | -$11M |
| 2024 Q4 |
| -0.14 |
| $0 |
| -$11M |
| 2024 Q3 | -0.26 | $0 | -$6M |